gsk3008356
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 14, 2016 (NCT02742766)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DGAT1 proteinINHIBITOR
Q9BRH5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk3008356
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04163263 | Phase 1 | Nov 4, 2019 | Boston Pharmaceuticals |
| NCT02742766 | Phase 1 | Mar 14, 2016 | GlaxoSmithKline, Nucleus Network Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2016 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1